ATLANTA, GA – – (Newsfile Corp. – January 23, 2023) – – Holzer & Holzer, LLC is investigating whether Surmodics, Inc. (“Surmodics” or the “Company”) (NASDAQ: SRDX) complied with federal securities laws. On January 19, 2023, the Company issued a press release regarding its premarket approval application (PMA) for SurVeil ™ stating: “the FDA indicated that the application is not currently approvable” and that “certain information within two general categories—biocompatibility and labeling—must be added by an amendment to the company’s PMA application to place it in approvable form.” Following that news, the Company’s stock dropped again.
If you purchased Surmodics stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at firstname.lastname@example.org or Joshua Karr, Esq. at email@example.com, call our toll-free number at (888) 508-6832, or visit our website at https://holzerlaw.com/case/surmodics/ to discuss your legal rights.